VolitionRX
Revolutionizing Cancer Diagnosis | Volition RX.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $1.9m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 570 % | 240 % | 153 % | 59 % | 206 % | 457 % | 165 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (28503 %) | (9542 %) | (4420 %) | (2073 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (29782 %) | (9879 %) | (4556 %) | (2186 %) | (438 %) | (36 %) | 66 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 17262 % | 4756 % | 2522 % | 1168 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
VolitionRx Limited is a multinational epigenetics company focused on developing simple, easy-to-use, and cost-effective blood tests to diagnose and monitor a range of life-altering diseases, including various cancers and conditions associated with NETosis, such as sepsis and COVID-19. The company operates in the healthcare diagnostics market, serving both human and veterinary clients. VolitionRx's business model revolves around leveraging its proprietary Nu.Q™ platform to create diagnostic tests that can be used in clinical settings for early disease detection and ongoing patient monitoring. The company generates revenue through licensing agreements, such as its recent $28 million deal with Heska Corporation to distribute a veterinary cancer screening test, as well as through direct sales and partnerships with healthcare providers and distributors. VolitionRx aims to improve patient outcomes by enabling earlier diagnosis and better disease management, ultimately enhancing quality of life.
Keywords: epigenetics, blood tests, disease diagnosis, cancer screening, NETosis, sepsis, COVID-19, healthcare diagnostics, veterinary, Nu.Q™ platform.